You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

List of Excipients in API tazarotene


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing tazarotene

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Allergan Inc TAZORAC tazarotene 0023-8335 ASCORBIC ACID
Allergan Inc TAZORAC tazarotene 0023-8335 BENZYL ALCOHOL
Allergan Inc TAZORAC tazarotene 0023-8335 BUTYLATED HYDROXYANISOLE
Allergan Inc TAZORAC tazarotene 0023-8335 BUTYLATED HYDROXYTOLUENE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Subscribe

Detailed excipient profiles for tazarotene

Excipient focus: ANHYDROUS CITRIC ACID

Excipient focus: ASCORBIC ACID

Excipient focus: BENZYL ALCOHOL

Excipient focus: BUTYLATED HYDROXYANISOLE

Excipient focus: BUTYLATED HYDROXYTOLUENE

Excipient focus: CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES

Excipient focus: CARBOMER 1342

Excipient focus: CARBOMER COPOLYMER TYPE A

Excipient focus: CARBOMER COPOLYMER TYPE B

Excipient focus: CARBOMER HOMOPOLYMER TYPE A

Excipient focus: CARBOMER HOMOPOLYMER TYPE B

Excipient focus: CETEARETH-12

Excipient focus: DIETHYL SEBACATE

Excipient focus: DIISOPROPYL ADIPATE

Excipient focus: EDETATE DISODIUM

Excipient focus: GLYCERYL CAPRYLOCAPRATE

Excipient focus: HEXYLENE GLYCOL

Excipient focus: LIGHT MINERAL OIL

Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES

Excipient focus: METHYLPARABEN

Excipient focus: MINERAL OIL

Excipient focus: POLOXAMER 407

Excipient focus: POLYETHYLENE GLYCOL 400

Excipient focus: POLYSORBATE 40

Excipient focus: POTASSIUM CITRATE

Excipient focus: POTASSIUM SORBATE

Excipient focus: PROPYLPARABEN

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SODIUM THIOSULFATE

Excipient focus: SORBIC ACID

Excipient focus: SORBITAN MONOOLEATE

Excipient focus: SORBITOL

Excipient focus: TROMETHAMINE

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group